Related Experiment Video
Updated: May 15, 2026

10:03
Comparative Study on the Polysaccharide Contents and Antioxidant Activities of Hippophae rhamnoides subsp. sinensis and Hippophae gyantsensis
Published on: August 15, 2025
Five new phenolic glycosides from Hedyotis scandens
Guo-Cai Wang1, Tao Li, Fang-Ye Deng
1Institute of Traditional Chinese Medicine and Natural Products, Jinan University, Guangzhou 510632, China. twangguocai@jnu.edu.cn
Bioorganic & Medicinal Chemistry Letters
|January 22, 2013
Summary
Researchers isolated five new phenolic glycosides from Hedyotis scandens. Two compounds demonstrated antiviral activity against respiratory syncytial virus (RSV), indicating potential therapeutic applications.
Area of Science:
- Natural Product Chemistry
- Pharmacology
- Virology
Background:
- Hedyotis scandens is a plant source of bioactive compounds.
- Phenolic glycosides and cyanogenic glycosides are classes of natural products with diverse biological activities.
- Respiratory Syncytial Virus (RSV) is a significant respiratory pathogen causing illness in all age groups.
Purpose of the Study:
- To isolate and characterize new compounds from Hedyotis scandens.
- To evaluate the in vitro antiviral activity of isolated compounds against RSV.
Main Methods:
- Isolation of compounds using chromatographic techniques.
- Structure elucidation of new compounds via spectroscopic analyses (NMR, MS) and acid hydrolysis.
- Antiviral activity assay using the cytopathic effect (CPE) reduction method.
Main Results:
- Five new phenolic glycosides, hedyotosides A-E (1-5), including a novel cyanogenic glycoside (1), were identified.
- Ten known compounds (6-15) were also isolated and identified.
- Compounds 6 and 15 exhibited anti-RSV activity with IC50 values of 20 μg/mL and 25 μg/mL, respectively.
Conclusions:
- Hedyotis scandens is a rich source of diverse phenolic glycosides.
- Compounds 6 and 15 possess significant in vitro antiviral properties against RSV.
- Further investigation into these compounds may lead to novel antiviral therapeutics.
